Back to Newsroom

Symic Biomedical Advances First Product Candidate, SB-030, into Clinical Development with Treatment of First Patient in SHIELD Trial

SAN FRANCISCO, Oct. 27, 2015 – Symic Biomedical, a clinical‐stage biotherapeutics platform company developing compounds that target the extracellular matrix (ECM), today announced the treatment of the first patient in its Phase 1/2 clinical Study in Humans to Investigate the Efficacy and Safety of Luminal SB‐030 Delivery in Peripheral Artery Disease (SHIELD Trial). The study will evaluate the safety and efficacy of SB‐030 (previously SBCV‐030), a locally applied, single‐use treatment for the reduction of neointimal hyperplasia resulting from the vascular injury following percutaneous transluminal angioplasty (PTA).

Click here to read more